Clinical trial

Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus…

NCT00192491 · MedImmune LLC, Industry · Completed

Key facts

NCT number NCT00192491
Title Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children
Official title A Randomized, Placebo-Controlled, Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, (MMRIIÒ) and Varicella (VARIVAXÒ) Vaccines Administered Concurrently to Healthy Children (AV018)
Lead sponsor MedImmune LLC, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Influenza
Intervention type Biological, Other
Interventions FluMist, Placebo
Enrollment 1,200
Start date Dec 1, 2000
Primary completion Sep 1, 2003
Completion Dec 1, 2003
First posted Sep 19, 2005
Last update posted Feb 8, 2008

At a glance

  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies